Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)
ID: 340173Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/340173

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-182.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting research grant applications for the Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional), aimed at advancing the development and testing of behavioral therapies for substance use disorders. This initiative encourages research that focuses on the efficacy of interventions, mechanisms of behavior change, and the optimization of treatment approaches, particularly for drug and alcohol dependence, through a structured three-stage research process. The program emphasizes the importance of innovative treatment strategies and community engagement to improve outcomes for diverse populations affected by addiction. Interested applicants can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with the application deadline set for March 21, 2025.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-182.html
    The Department of Health and Human Services, through the National Institute on Drug Abuse (NIDA), is inviting research grant applications for its Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional). This initiative, represented by FOA number PAR-22-182, seeks to advance the development and testing of behavioral and integrative therapies for substance use disorders, including drug and alcohol dependence. The funding is aimed at various stages of treatment research, emphasizing the importance of creating and refining interventions, assessing efficacy in controlled and real-world settings, and exploring mechanisms of behavior change. Key processes involve conducting research across three stages: Stage I focuses on developing and pilot testing new or modified interventions; Stage II tests these interventions for efficacy in structured research environments; and Stage III assesses their effectiveness in community settings. The aim is to foster innovation in treatment approaches, particularly by leveraging recent advancements in neuroscience and technology. Applications from a broad range of eligible institutions and individuals are encouraged, with funding contingent upon NIH appropriations. The initiative reflects a commitment to improving treatment outcomes for diverse populations and advancing the science of addiction treatment through rigorous research and community engagement.
    Similar Opportunities
    Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) aimed at advancing research in behavioral and integrative treatments for substance use and dependence. This program encourages the development and testing of innovative behavioral therapies through a structured approach that includes intervention generation, efficacy testing in research settings, and real-world efficacy assessments, with a focus on diverse populations and the use of technology. The funding amount is contingent on NIH appropriations, with a maximum project period of five years, and applications are due by February 5, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-299.html.
    Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), a federal grant opportunity aimed at funding research for developing and testing behavioral treatments for substance use and dependence. This initiative seeks to encourage research that tests the efficacy of behavioral interventions, examines mechanisms of behavior change, and optimizes treatment approaches, particularly for individuals with comorbidities and those in drug abuse treatment. The program is crucial for advancing substance abuse treatment and addressing health disparities, with a maximum funding amount of $450,000 available over three years. Interested applicants, including various educational institutions and community organizations, must submit their proposals by March 21, 2025, and can find additional information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alcohol Treatment, Pharmacotherapy, and Recovery Research grant, specifically under the R01 Clinical Trial Required mechanism. This funding opportunity aims to advance research on Alcohol Use Disorder (AUD) by focusing on various aspects such as medication development, behavioral therapies, recovery mechanisms, and innovative treatment technologies. The NIH emphasizes the importance of addressing AUD, particularly for underserved populations, and seeks projects that translate neuroscience research into practical applications. Interested applicants can apply for a grant with an award ceiling of $500,000, with the application process opening on January 5, 2025, and submissions due by September 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PA-25-163.html.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)" aimed at advancing research in the treatment and recovery from alcohol use disorder (AUD). This grant supports clinical trials focusing on various aspects of AUD, including medication development, behavioral therapies, and innovative treatment technologies, particularly for populations facing health disparities. The funding is crucial for enhancing the understanding and efficacy of AUD treatments, ultimately contributing to improved public health outcomes. Eligible applicants can receive up to $500,000 in direct costs over a maximum project period of five years, with key submission deadlines on October 5, 2023, and February 5, 2024. For more information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-250.html.
    Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R34 Clinical Trial mechanism focused on Alcohol Treatment, Pharmacotherapy, and Recovery Research. This initiative aims to enhance understanding and treatment strategies for Alcohol Use Disorder (AUD) through clinical trials, with a particular emphasis on increasing access to treatment, improving treatment appeal, examining cost structures, and addressing health disparities among affected populations. The program is open to a diverse range of applicants, including educational institutions, nonprofits, and government agencies, with funding limits set at $450,000 over a maximum three-year project period. Interested parties must submit their applications by October 16, 2023, and can direct inquiries to grantsinfo@nih.gov for further information.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.